Literature DB >> 1944755

A randomized controlled trial of low-dose prednisone and ciclosporin versus high-dose prednisone in nephrotic syndrome of children.

A Tejani1, M Suthanthiran, A Pomrantz.   

Abstract

Twenty-eight patients with an onset of nephrotic syndrome within 1 year were randomized to receive either ciclosporin and low-dose prednisone or high-dose prednisone alone. Both groups were treated for 8 weeks. Thirteen of 14 children receiving combined therapy underwent remission versus only 8 of 14 children receiving prednisone alone (p less than 0.05). However, there was no difference between the two groups as regards the duration of remission after discontinuation of therapy. In patients receiving combined therapy, immunological studies showed that high interleukin producers had a more sustained remission. There was no evidence of ciclosporin-induced nephrotoxicity in this short-term therapeutic trial.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1944755     DOI: 10.1159/000186526

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  13 in total

1.  Combined cyclosporine and prednisolone therapy using cyclosporine blood concentration monitoring for adult patients with new-onset minimal change nephrotic syndrome: a single-center pilot randomized trial.

Authors:  Sayuri Shirai; Naohiko Imai; Shina Sueki; Katsuomi Matsui; Naoto Tominaga; Tsutomu Sakurada; Takashi Yasuda; Kenjiro Kimura; Yugo Shibagaki
Journal:  Clin Exp Nephrol       Date:  2017-07-11       Impact factor: 2.801

Review 2.  Consensus statement on management and audit potential for steroid responsive nephrotic syndrome. Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians.

Authors: 
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

Review 3.  Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis : an update of treatment options for children.

Authors:  Jochen H H Ehrich; Lars Pape; Mario Schiffer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 4.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

5.  Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome.

Authors:  Yuko Hamasaki; Norishige Yoshikawa; Shinzaburo Hattori; Satoshi Sasaki; Kazumoto Iijima; Koichi Nakanishi; Takeshi Matsuyama; Kenji Ishikura; Nahoko Yata; Tetsuji Kaneko; Masataka Honda
Journal:  Pediatr Nephrol       Date:  2009-11       Impact factor: 3.714

6.  Long-term cyclosporin A treatment of minimal-change nephrotic syndrome of childhood.

Authors:  S A Hulton; T J Neuhaus; M J Dillon; T M Barratt
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

7.  Prediction of high-degree steroid dependency in pediatric idiopathic nephrotic syndrome.

Authors:  Béatrice Letavernier; Emmanuel Letavernier; Sandrine Leroy; Valérie Baudet-Bonneville; Albert Bensman; Tim Ulinski
Journal:  Pediatr Nephrol       Date:  2008-07-11       Impact factor: 3.714

8.  Alternative treatment to corticosteroids in steroid sensitive idiopathic nephrotic syndrome.

Authors:  T J Neuhaus; J Fay; M J Dillon; R S Trompeter; T M Barratt
Journal:  Arch Dis Child       Date:  1994-12       Impact factor: 3.791

9.  Up-regulation of interleukin-2 mRNA in children with idiopathic nephrotic syndrome.

Authors:  Hironobu Shimoyama; Mitsuru Nakajima; Hiroyuki Naka; Yoshiyuki Maruhashi; Hideki Akazawa; Taku Ueda; Masayuki Nishiguchi; Yoko Yamoto; Hidekazu Kamitsuji; Akira Yoshioka
Journal:  Pediatr Nephrol       Date:  2004-08-07       Impact factor: 3.714

10.  Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children.

Authors:  E Jacqz-Aigrain; C Montes; P Brun; C Loirat
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.